PixarBio CEO's Greed Drove Stock Fraud, Boston Jury Hears

Law360, Boston (October 9, 2019, 10:18 AM EDT) -- In his quest to be rich, the CEO of a Boston-based biotech company lied to investors about himself and his company in order to drive up the company's stock price, a federal jury heard Wednesday morning as the executive's trial began.

Frank Reynolds told investors his company, PixarBio, raised more than $30 million and was developing a drug that could end opioid addiction and was headed toward U.S. Food and Drug Administration approval within two years, Assistant U.S. Attorney Leslie Wright told the jury during opening statements. But it was all a lie, the prosecutor said.

"Billionaire with a 'B,' that's...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS